Adaptimmune

  • Home
  • Our Company
    • Overview arrow_forward
    • Board of Directors arrow_forward
    • Leadership Team arrow_forward
  • Products
  • Pipeline
    • Overview arrow_forward
    • Afami-cel arrow_forward
    • Lete-cel arrow_forward
    • Uza-cel arrow_forward
  • Technology
    • Overview arrow_forward
    • Manufacturing arrow_forward
    • Publications arrow_forward
  • Patients & Families
    • Overview arrow_forward
    • Taking Part in Our Clinical Trials arrow_forward
    • Videos arrow_forward
  • Clinical Trials
    • Overview arrow_forward
    • Expanded Access Policy arrow_forward
  • Investors & Media
    • Overview arrow_forward
    • News Center arrow_forward
    • Financial Info and Governance arrow_forward
    • Stock Data arrow_forward
    • SEC Filings arrow_forward
  • Contact
  • Careers
    • Overview arrow_forward
    • US Careers arrow_forward
    • UK Careers arrow_forward

Annual Shareholder Meeting

Investors & Media

Investors & Media

  • Overview
  • News Center
    • Media Resources
    • Corporate Presentations
    • Press Releases
    • Publications
    • Events
    • Email Alerts
  • Financial Info and Governance
    • General Meeting (merger)
    • Company Information
    • Leadership Team
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Annual Shareholder Meeting
    • FAQ
    • Contacts
    • Adaptimmune Ltd Report
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Financial Info and Governance

  • General Meeting (merger)
  • Company Information
  • Leadership Team
  • Financial Results
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Board of Directors
  • Board Committees
  • Governance Documents
  • Annual Shareholder Meeting
  • FAQ
  • Contacts
  • Adaptimmune Ltd Report

2025

  • picture_as_pdf Notice of 2025 Annual General Meeting
  • picture_as_pdf Annual Report (UK) 2024
  • picture_as_pdf Form of Proxy (ordinary shareholder) 2025 AGM
  • picture_as_pdf Definitive Proxy Statement
  • picture_as_pdf 10-K 2024
  • picture_as_pdf 2025 Employee Share Option Scheme
  • picture_as_pdf 2025 Non-Employee Share Option Scheme

2024

  • picture_as_pdf Notice of 2024 Annual General Meeting
  • picture_as_pdf Annual Report (UK) 2023
  • picture_as_pdf Form of Proxy (ordinary shareholder) 2024 AGM
  • picture_as_pdf Definitive Proxy Statement
  • picture_as_pdf 10-K 2023

2023

  • picture_as_pdf Notice of 2023 Annual General Meeting
  • picture_as_pdf Annual Report (UK) 2022
  • picture_as_pdf Form of Proxy (ordinary shareholder) 2023 AGM
  • picture_as_pdf Definitive Proxy Statement
  • picture_as_pdf 10-K 2022

2022

  • picture_as_pdf Notice of 2022 Annual General Meeting
  • picture_as_pdf Annual Report (UK) 2021
  • picture_as_pdf Form of Proxy (ordinary shareholder) 2022 AGM
  • picture_as_pdf Definitive Proxy Statement
  • picture_as_pdf 10-K 2021

2021

  • picture_as_pdf Notice of 2021 Annual General Meeting
  • picture_as_pdf Annual Report (UK) 2020
  • picture_as_pdf Form of Proxy (ordinary shareholder) 2021 AGM
  • picture_as_pdf Definitive Proxy Statement
  • picture_as_pdf 10-K 2020

2020

  • picture_as_pdf Notice of 2020 Annual General Meeting
  • picture_as_pdf Annual Report (UK) (year ended 31 December 2019)
  • picture_as_pdf Chairman Letter for 2020 AGM
  • picture_as_pdf Form of Proxy (ordinary shareholder) 2020 AGM
  • picture_as_pdf Definitive Proxy Statement
  • picture_as_pdf 10-K 2019

2019

  • picture_as_pdf Notice of 2019 Annual General Meeting
  • picture_as_pdf Annual Report (UK) (year ended 31 December 2018)
  • picture_as_pdf Chairman Letter for 2019 AGM
  • picture_as_pdf Form of Proxy (ordinary shareholder) 2019 AGM
  • picture_as_pdf Definitive Proxy Statement
  • picture_as_pdf 10-K 2018

2018

  • picture_as_pdf Notice of 2018 Annual General Meeting
  • picture_as_pdf Chairman Letter for 2018 AGM
  • picture_as_pdf Form of Proxy (ordinary shareholder) 2018 AGM
  • picture_as_pdf Annual Report (UK) (year ended 31 December 2017)
  • picture_as_pdf Definitive Proxy Statement
  • picture_as_pdf 10-K 2017

2017

  • picture_as_pdf Annual Report (UK) (year ended 31 December 2016)
  • picture_as_pdf Form of Proxy (ordinary shareholder) 2017 AGM
  • picture_as_pdf Chairman Letter for 2017 AGM
  • picture_as_pdf Notice of 2017 Annual General Meeting
  • picture_as_pdf Definitive Proxy Statement
  • picture_as_pdf 10-K 2016

2016

  • picture_as_pdf Notice of 2016 Annual General Meeting
  • picture_as_pdf Annual Report (UK) (period ended 31 December 2015)
  • picture_as_pdf Articles of Association (redline of proposed amends)
  • picture_as_pdf Proposed new Articles of Association

2015

  • picture_as_pdf Notice of 2015 Annual General Meeting
  • picture_as_pdf Annual Report (UK) (period ended 30 June 2015)
Adaptimmune
Disclosures Privacy Policy Disclaimer Search Sitemap Terms of Use Supply Terms Cookie Policy Manage Cookie Preferences
Linedin Twitter Youtube
© 2025 Adaptimmune. All Rights Reserved.